Prostate Cancer - Results from #300

Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data. September 6, 2024

Comparison of Pathologist and Artificial Intelligence-based Grading for Prediction of Metastatic Outcomes After Radical Prostatectomy. September 6, 2024

The third symposium on treatment-induced neuroendocrine prostate cancer: insights and future directions. September 5, 2024

A Multi-Institutional Study of MR/US Fusion Guided Nanoparticle Directed Focal Therapy for Prostate Ablation. September 5, 2024

Talazoparib for the treatment of prostate cancer. September 5, 2024

PSMA PET improves characterization of dural-based intracranial lesions in patients with metastatic prostate cancer. September 5, 2024

Pelvic Lymph Node Dissection: A Comparison Among Extraperitoneal Single-port and Transperitoneal Multiport Radical Prostatectomy-A Single-center Experience. September 5, 2024

The Man Van: A pilot study of using mobile targeted case-finding to address health inequalities in prostate cancer. September 5, 2024

The Proteogenomics of Prostate Cancer Radioresistance. September 5, 2024

Prostate-specific Antigen Nadir and Cancer-Control Outcomes in Real-world Apalutamide-treated Metastatic Hormone-Sensitive Prostate Cancer Patients: A Single-Center Analysis. September 4, 2024

Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis. September 4, 2024

A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease. September 4, 2024

Androgen production, uptake, and conversion (APUC) genes define prostate cancer patients with distinct clinical outcomes. September 4, 2024

Statin concentration in prostatic tissue is subtype- and dose-dependent. September 4, 2024

Final Results of the ANDROCAN Study: Histopathological Characteristics and Biochemical Recurrence at 5 Years of Localized Prostate Cancer According to Preoperative Gonadal Status. September 4, 2024

Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System. September 4, 2024

Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-/[18F]F-PSMA-11/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET/CT: a pilot study. September 4, 2024

MRI-based PI-RADS score predicts ISUP upgrading and adverse pathology at radical prostatectomy in men with biopsy ISUP 1 prostate cancer. September 3, 2024

Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047). September 3, 2024

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Regi September 3, 2024

Page 16 of 1435